- EffiX™ is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli expression system. It serves as a comprehensive solution for the development and manufacturing of ...

SHANGHAI, Aug. 11, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of WuXia293 Stable ...

WuXiUI™ ultra-intensified fed-batch platform offers a new process option for maximum flexibility to meet various clients' needs in biologics development and manufacture. The platform can significantly ...

The WuXiHigh™2.0 technology platform harnesses proprietary excipient blends and expertise to enable concentrations up to 230 mg/mL It reduces viscosity by up to 90% while maintaining formulation ...

SHANGHAI, Aug. 30, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has ...

Duality to grant license of DITAC (Duality Immune Toxin Antibody Conjugates) platform to Adcendo for its lead uPARAP ADC program Duality to receive upfront payment, development, regulatory and ...

CLEVELAND, Aug. 29, 2023 /PRNewswire/ -- IdentifySensors ® Biologics, a leading developer of digital diagnostic technologies, has partnered with Atlanta-based East West Manufacturing to produce ...